Epilepsy Research Journal
Epilepsy Research RSS feed.
Updated: 1 hour 6 min ago
Epilepsy affects 50 million people worldwide according to the World Health Organization and 20–30% of patients develop resistance to antiepileptic drugs. The side effects of antiepileptic treatments represent a heavy economic burden (de Kinderen et al., 2014) and have a significantly negative impact on the quality of life (Luoni et al., 2011).
We are developing a non-invasive facial nerve stimulator device as an emergency treatment for ischemic stroke. It is well-known that electric stimulation of the parasympathetic petrosal components of the facial nerve causes dilation of the cranial arteries and an increase in cerebral blood flow in normal animals (Forbes et al., 1937, 1939; Meyer et al., 1967; Adams et al., 1989; Goadsby, 1989, 1990a,b, 1991; Goadsby and Hoskin, 1994; Sato et al., 1997; Toda et al., 2000a,b) and in animals with brain ischemia (Yarnitsky et al., 2005, 2006; Henninger and Fisher, 2007; Takahashi et al., 2011).
SCN1A is arguably the most important epilepsy gene with vast clinical heterogeneity. Not only can different SCN1A variants result in variable epilepsy phenotypes, but the same variant, even within the one family, can result in very different clinical outcomes. We see no clearer example of this than in families with genetic epilepsy with febrile seizures plus (GEFS+).
Utility of gray-matter segmentation of ictal-Interictal perfusion SPECT and interictal F-FDG-PET in medically refractory epilepsy
Epilepsy, or recurrent unprovoked seizures, is estimated to affect 50 million people worldwide with an incidence of 44 per 100,000 person-years (Hauser et al., 1993). Twenty-nine percent of people with epilepsy are considered to have medically refractory epilepsy, which is associated with poor quality of life and increased morbidity and mortality (Kwan and Brodie, 2000; Lee et al., 2005; Shandal et al., 2012).
Seizure Detection and Neuromodulation: A Summary of Data Presented at the XIII Conference on New Antiepileptic Drug and Devices (EILAT XIII)
The Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII) took place in Madrid, Spain from June 26th to 29th 2016. For the first time, the last day of the conference focused solely on new medical devices and neuromodulation. The current article summarises the presentations of that day, focusing first on EEG- and ECG based methods and devices for seizure detection. These methodologies form the basis for novel cardiac-based methods of vagal nerve and responsive deep brain stimulation that rely on the prediction or early detection of seizures and that are also included in this article.